BCYC Bicycle Therapeutics plc - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BCYC Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$6.95
Analyst Target
$21.5
+209.4%
Upside
52W High
$13.63
52W Low
$6.03
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.
Key Strengths
Exceptional year-over-year revenue growth of 338.50% suggests strong commercial or partnership momentum
Exceptionally strong liquidity position with current ratio of 10.66 and quick ratio of 10.33
Very low leverage with Debt/Equity ratio of just 0.01, reducing financial risk
Analyst consensus supports strong upside with a $21.50 target price, implying over 200% potential return
Recent weekly price performance shows positive momentum (+6.8%) amid broader negative trends
Key Risks
Piotroski F-Score of 4 indicates weak financial health and limited operational strength
Operating margin of -558.64% reflects severe unprofitability and cost inefficiency
Negative ROE (-34.59%) and negative ROA (-20.59%) demonstrate poor capital utilization
Insider selling activity in the last 6 months signals lack of confidence from corporate insiders
Forward P/E of -1.99 and negative earnings trend indicate no near-term profitability
AI Fair Value Estimate
Based on comprehensive analysis
$21.5
+209.4% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BCYC against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BCYC from our newsroom.
Newest → oldest
No matching news yet.